期刊文献+

对小鼠黑色素瘤细胞肺转移的抑制作用mGM-CSF基因转染 被引量:1

Inhibition of lung metastasis of B16 melanoma cells transfected with murine granulocyte-macrophage colony-stimulating factor in mice
下载PDF
导出
摘要 目的探讨小鼠粒细胞巨噬细胞-集落刺激因子(mGM-CSF)基因转导对B16黑色素瘤细胞肺转移的抑制效果.方法应用脂质体将含有mGM-CSF基因的真核表达载体转染B16小鼠黑色素瘤细胞,经G418加压筛选后,挑选表达mGM-CSF基因的B16黑色素瘤细胞.观察转导或未转导mGM-CSF基因的B16黑色素瘤细胞在Balb/c小鼠体内的肺转移.结果转导mGM-CSF基因的B16黑色素瘤细胞可以稳定表达mGM-CSF,在小鼠模型上其肺转移灶数目显著少于未转染基因的黑色素瘤细胞对照组,二者差异显著(n=5,125.8±34.3vs27.8±24.0,P<0.01).结论mGM-CSF转导可显著抑制小鼠黑色素瘤细胞B16的肺转移,提示GM-CSF具有治疗黑色素瘤的临床应用前景. AIM: To investigate the inhibition of lung metastasis of melanoma by a tumor vaccine of B16 melanoma cells transfected with murine granulocyte-macrophage colony-stimulating factor (mGM-CSF). METHODS: The murine melanoma cell line B16 was transfected with the recombinant plasmid containing mGM- CSF. A cell line stably expressing mGM-CSF was obtained by G418 selection. The Balb/c mice were administered i. v. with B16 cells transfected with or without mGM-CSF respectively and the lung metastasis was examined 2 weeks later. RESULTS: The recombinant cell line B16-TR was established after mGM-CSF tranfection and the expression of mGM-CSF was confirmed by RT- PCR. The number of lung metastatic lesions of mice treated with B16-TR was significantly fewer than that of mice treated with B16 (n=5, 125. 8 ± 34. 3 vs 27. 8 ±24. 0, P 〈0. 01). CONCLUSION: The mGM-CSF transfection can significantly suppress the lung metastasis of melanoma in mice. The GM-CSF can be a promising adjuvant in the immunotherapy of melanoma.
出处 《第四军医大学学报》 北大核心 2006年第6期484-486,共3页 Journal of the Fourth Military Medical University
基金 国家863计划资助项目(2001AA217131)
关键词 黑色素瘤 小鼠 粒细胞巨噬细胞-集落刺激因子 肺肿瘤/继发性 癌症疫苗 melanoma mice granulocyte-macrophage colonystimulating factor lung neoplasms/secondary cancer vaccines
  • 相关文献

参考文献10

  • 1Chung ES, Sabel MS, Sondak VK. Current state of treatment for primary cutaneous melanoma [ J ]. Clin Exp Med, 2004, 4 (2):65 - 77.
  • 2Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma [J]. N Engl J Med, 2004, 351(10) : 998-1012.
  • 3Stone A, Cooper J, Koenig KL, et al. A comparison of survival rates for treatment of melanoma metastatic to the brain [J]. Cancer Invest,2004,22 ( 4 ) :492 - 497.
  • 4Elliott B, Dalgleish A. Melanoma vaccines [ J ]. Hosp Med, 2004,65( 11 ) :668 -673.
  • 5Shurin MR, Kirkwood JM, Esche C. Cytokine-based therapy for melanoma: pre-clinical studies [ J ]. Forum (Genova) , 2000,10 ( 3 ) :204 - 226.
  • 6Morse MA, Chui S, Hobeika A, et al. Recent developments in thempeutic cancer vaccines [ J ]. Nat Clin Pract Oncol. 2005,2 ( 2 ) :108 - 113.
  • 7Komenaka I, Hoerig H, Kaufman HL. Immunotherapy for melanoma[J]. Clin Dermatol. 2004,22(3) :251-265.
  • 8Nemunaitis J, Nemunaitis J. Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine : focus [ correction to fcous] on non-small-cell lung cancer [J]. Clin Lung Cancer. 2003,5(3) :148 -57.
  • 9Rosenberg SA. Shedding light on immunotherapy for cancer [ J ]. N Engl J Med. 2004, 350(14) :1461 -1463.
  • 10Stagg J, Wu JH, Bouganim N, et al. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy [J]. Cancer Res,2004, 64 (24) :8795 - 8879.

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部